AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Dr. Reddy's Laboratories Limited American Depositary Shares
XNYS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SHMCN3
13.21▼ 0.02 (-0.15%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
13.23
Day's Range
13.18 – 13.57
52-Week Range
11.36 – 15.67
Volume
3.9M
Avg Volume
3.0M
Share Statistics
Shares Outstanding
Employees
27.8K
Exchange
XNYS
Listed
2001-04-11
Share count as of March 31, 2026

Dr. Reddy's Laboratories Limited American Depositary Shares (RDY) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Dr. Reddy's Laboratories Limited American Depositary Shares (RDY)
What is Dr. Reddy's Laboratories Limited American Depositary Shares's Market Cap?
Dr. Reddy's Laboratories Limited American Depositary Shares's Market Cap is $11.0B, based on as-reported figures from SEC (XBRL) filings.
What is Dr. Reddy's Laboratories Limited American Depositary Shares's Enterprise Value?
Dr. Reddy's Laboratories Limited American Depositary Shares's Enterprise Value is $11.2B, based on as-reported figures from SEC (XBRL) filings.
What is Dr. Reddy's Laboratories Limited American Depositary Shares's Net Debt?
Dr. Reddy's Laboratories Limited American Depositary Shares's Net Debt is $194.0M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · RDYAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of INR, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Mar 31, 2025Mar 31, 2024Mar 31, 2023Mar 31, 2022Mar 31, 2021Mar 31, 2020Mar 31, 2019Mar 31, 2018
Analysis of income and expense [abstract]
Revenues
Cost of revenues
Gross profit
Selling, general and administrative expenses
Research and development expenses
Impairment of non-current assets, net
Other income, net
Total operating expenses
Results from operating activities (A)
Finance income
Finance expense
Finance income, net (B)
Share of profit of equity accounted investees, net of tax (C)
Profit before tax [(A)+(B)+(C)]
Tax expense, net
Profit for the year
Attributable to:
Equity holders of the parent company
Non-controlling interests
Earnings per share attributable to equity holders of the parent company
Basic earnings per share of Rs.1/- each
Diluted earnings per share of Rs.1/- each